Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
CTNNB1 mutation represents a recurrent driver molecular alteration in a subset of endometrial stromal tumors.
Dundr P et al.
Virchows Archiv : an International Journal of Pathology, 2026
CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.
Hirsch RM et al.
Jci Insight, 2026
Hepatoblastoma Cell Lines: Past, Present and Future.
Prochownik EV et al.
Cells, 2025
Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (CTNNB1) mutations.
Hewer E et al.
Journal of Clinical Pathology, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
WNT-β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials.
Lehrich BM et al.
Nature Reviews. Gastroenterology & Hepatology, 2025
CTNNB1 mutations in serum amyloid A-positive hepatocellular neoplasm/inflammatory hepatocellular adenoma arising in alcoholic cirrhosis.
Sasaki M et al.
Human Pathology, 2025
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.
Kulhavy J et al.
Jco Precision Oncology, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Novel CTNNB1 gene mutations reveal critical pathogenic mechanisms in pediatric hepatoblastoma.
Kumar S et al.
Pediatric Surgery International, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer.
Wong AM et al.
Jhep Reports : Innovation in Hepatology, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors.
Chan HT et al.
Clinical Chemistry, 2025
Prostate Ductal Adenocarcinoma Revisited: Clinicopathological and Genomic Characterization Identifies Heterogenous Group of Diseases with Implications for Patient Management.
Cai Q et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
High-Frequency Mutations in TP53, AXIN1, CTNNB1, and KRAS, and Polymorphisms in JAK1 Genes Among Mongolian HCC Patients.
Bold N et al.
Cancer Reports (hoboken, N.j.), 2025
Analyses of CTNNB1 mutation and expression and clinicopathological characteristics in 179 cases of solid-pseudopapillary neoplasm of the pancreas.
Zhao S et al.
Journal of Hepato-biliary-pancreatic Sciences, 2025
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition.
Zhang T et al.
Biorxiv : the Preprint Server for Biology, 2025
Ovarian endometrioid carcinoma with a sex cord-like pattern: a morphological, immunohistochemical, and molecular analysis.
Travaglino A et al.
Virchows Archiv : an International Journal of Pathology, 2025
Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.
Yao J et al.
Frontiers in Immunology, 2025
Evaluation of cell-free DNA from papanicolaou smears and peripheral blood to detect endometrial cancer.
Wang Y et al.
Frontiers in Oncology, 2025
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
Oncogenic composite mutations can be predicted by co-mutations and their chromosomal location.
Küçükosmanoglu A et al.
Molecular Oncology, 2024
Endometrioid ovarian carcinoma landscape: pathological and molecular characterization.
de Nonneville A et al.
Molecular Oncology, 2024
Activation of the Wnt/β-catenin signaling pathway and CTNNB1 mutations in canine intestinal epithelial proliferative lesions.
Ishikawa K et al.
The Journal of Veterinary Medical Science, 2024
Molecular profiling of primary endometrioid endometrial cancer and matched lung metastases: CTNNB1 mutation as a potential driver.
Gordhandas S et al.
Gynecologic Oncology Reports, 2024
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response.
Hu Z et al.
Nature Genetics, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
Mathew A et al.
Jco Global Oncology, 2024
Detection of driver mutations and genomic signatures in endometrial cancers using artificial intelligence algorithms.
Stan A et al.
Plos One, 2024
DegronMD: Leveraging Evolutionary and Structural Features for Deciphering Protein-Targeted Degradation, Mutations, and Drug Response to Degrons.
Xu H et al.
Molecular Biology and Evolution, 2023
CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.
Ning Q et al.
Journal of Viral Hepatitis, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Infantile Sinonasal Myxoma Is Clinically and Genetically Distinct From Other Myxomas of the Craniofacial Bones and From Desmoid Fibromatosis.
Odintsov I et al.
The American Journal of Surgical Pathology, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma.
Fang J et al.
Nature Communications, 2023
Occurrence of Hepatoblastomas in Patients with Beckwith-Wiedemann Spectrum (BWSp).
Klein SD et al.
Cancers, 2023
Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care.
Liu A et al.
Hematology Reports, 2023
Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.
Xie J et al.
Bmc Cancer, 2023
Targeted next-generation sequencing reveals activating CTNNB1 mutations in SMARCA4/BRG1-deficient sinonasal carcinomas: a report of two new cases and a brief review of the literature with an emphasis on histogenesis.
Zhao M et al.
Virchows Archiv : an International Journal of Pathology, 2023
Recommending revised hepatoblastoma surveillance in children with a pathogenic ARID1A variant. Reply to "Cancer in ARID1A-Coffin-Siris syndrome: Review and report of a child with hepatoblastoma" by Cárcamo et al. 2022.
van der Sluijs PJ et al.
European Journal of Medical Genetics, 2023